Navigation Links
Alexza to Webcast Investor and Analyst Day Presentations

MOUNTAIN VIEW, Calif., April 22 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will host a live audio webcast of presentations given at the Company's Investor and Analyst Day on Tuesday, April 29th, 2008. Leading medical experts will discuss the Phase 1 and Phase 2 results of the Company's clinical trials, provide an overview of the Phase 3 trial design for AZ-004 (Staccato(R) loxapine), and discuss the role that AZ-004 may play in treating acute agitation in schizophrenic or bipolar disorder patients. Alexza senior management will also provide an overview of Alexza's other clinical stage product candidates.

What: Presentations (Audio & Slides)

Who: Dr. Michael Allen - University of Colorado Health Sciences


Associate Professor of Psychiatry

Director, Emergency and Consultation Psychiatry

Co-Director, Mood Disorders Program

Past President and Trustee, American Association for

Emergency Psychiatry

Dr. Carol Tamminga -- University of Texas Southwestern

Medical Center

Professor of Psychiatry

Vice Chair for Clinical Research

Chief of Translational Neuroscience Research in


Communities Foundation of Texas Chair in Brain Science

When: Tuesday, April 29th, 2008 at 12:15-3:00 p.m. EDT




How: Live over the Internet -- Simply log on to the Web at the

address above and register for the event (approximately 10

minutes beforehand)

If you are unable to participate during the live webcast, the call will be archived on Alexza's website at

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at

Safe Harbor Statement

The anticipated webcast and presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings. Forward-looking statements contained in the webcast and presentations are made as of their date of presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
3. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
4. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
5. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
6. Johnson & Johnson to Webcast Annual Meeting of Shareholders
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
9. ResMed to Webcast Third Quarter 2008 Earnings Conference Call
10. CTG Announces 2008 First Quarter Conference Call and Webcast Information
11. MSA Schedules First Quarter Earnings Webcast
Post Your Comments:
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... University of Toronto and the University of British Columbia suggested that laws requiring bicyclists ... The article explains that part of the reason for the controversial conclusion is that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... ... Lizzie’s Lice Pickers just announced a special promotion that will run throughout ... of lice treatment product. In addition, customers will receive a complimentary head Check when ... is a sure way to ruin the holidays, so we encourage all of our ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community ... 30 (see Table 1-1 ). More than 3.7 billion people under the age ... type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . , ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology: